Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis
- PMID: 17664268
- PMCID: PMC2168297
- DOI: 10.1128/IAI.00411-07
Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis
Abstract
Neisseria meningitidis serogroup B is a major cause of bacterial meningitis in younger populations. The available vaccines are based on outer membrane vesicles obtained from wild-type strains. In children less than 2 years old they confer protection only against strains expressing homologous PorA, a major, variable outer membrane protein (OMP). We genetically modified a strain in order to eliminate PorA and to overproduce one or several minor and conserved OMPs. Using a mouse model mimicking children's PorA-specific bactericidal activity, it was demonstrated that overproduction of more than one minor OMP is required to elicit antibodies able to induce complement-mediated killing of strains expressing heterologous PorA. It is concluded that a critical density of bactericidal antibodies needs to be reached at the surface of meningococci to induce complement-mediated killing. With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection.
Figures




Similar articles
-
Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.Vaccine. 2020 Feb 28;38(10):2396-2405. doi: 10.1016/j.vaccine.2020.01.038. Epub 2020 Feb 7. Vaccine. 2020. PMID: 32037226 Free PMC article.
-
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.Infect Immun. 1996 Jul;64(7):2745-51. doi: 10.1128/iai.64.7.2745-2751.1996. Infect Immun. 1996. PMID: 8698504 Free PMC article. Clinical Trial.
-
A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis.J Immunol. 2001 Dec 1;167(11):6487-96. doi: 10.4049/jimmunol.167.11.6487. J Immunol. 2001. PMID: 11714816
-
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.Vaccine. 2009 Jun 24;27 Suppl 2:B112-6. doi: 10.1016/j.vaccine.2009.04.065. Epub 2009 May 21. Vaccine. 2009. PMID: 19464093 Review.
-
Meningococcal surrogates of protection--serum bactericidal antibody activity.Vaccine. 2005 Mar 18;23(17-18):2222-7. doi: 10.1016/j.vaccine.2005.01.051. Vaccine. 2005. PMID: 15755600 Review.
Cited by
-
Meningococcal serogroup B vaccines: will they live up to expectations?Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41. Expert Rev Vaccines. 2011. PMID: 21604975 Free PMC article. No abstract available.
-
A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups.Mol Immunol. 2009 May;46(8-9):1647-53. doi: 10.1016/j.molimm.2009.02.021. Epub 2009 Mar 14. Mol Immunol. 2009. PMID: 19286260 Free PMC article.
-
The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).Ann Med Surg (Lond). 2013 Nov 4;2(2):53-6. doi: 10.1016/S2049-0801(13)70037-2. eCollection 2013. Ann Med Surg (Lond). 2013. PMID: 25628885 Free PMC article. Review.
-
Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.PLoS One. 2013 Sep 6;8(9):e72003. doi: 10.1371/journal.pone.0072003. eCollection 2013. PLoS One. 2013. PMID: 24039731 Free PMC article.
-
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.Infect Immun. 2008 Sep;76(9):4232-40. doi: 10.1128/IAI.00367-08. Epub 2008 Jun 30. Infect Immun. 2008. PMID: 18591239 Free PMC article.
References
-
- Bos, M. P., and J. Tommassen. 2004. Biogenesis of the Gram-negative bacterial outer membrane. Curr. Opin. Microbiol. 7:610-616. - PubMed
-
- Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Aricò, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical